Laryngopharyngeal reflux disease: a pilot study with a new multicomponent

Area of Science:

• Otolaryngology
• Gastroenterology
• Pharmacology

Background:

• Laryngopharyngeal reflux disease (LPRD) presents challenges in management.
• Evaluating novel therapeutic devices is crucial for LPRD treatment.
• A multicomponent device with Gingigel Pro®, sodium alginate, Tamarindus indica, hyaluronic acid, and vegetal extracts was assessed.

Purpose of the Study:

• To assess the efficacy and safety of a new multicomponent medical device for LPRD.
• To evaluate improvements in subjective reflux symptoms and objective laryngoscopic signs.
• To explore treatment outcomes based on symptom duration.

Main Methods:

• Prospective observational study of 22 adult LPRD patients.
• Treatment involved the device (one stick twice daily for 2 months) and counseling.
• Outcome measures included Revised Reflux Symptom Index (R-RSI), Voice Handicap Index-10 (VHI-10), and Reflux Sign Assessment (RSA).

Main Results:

• Significant improvements observed in R-RSI, VHI-10, and RSA scores post-treatment (P<0.0001).
• Pathological R-RSI scores reduced from 100% to 9.1%; pathological RSA scores decreased from 100% to 59.1%.
• Early symptom onset (0-4 months) correlated with greater symptom and sign improvement.

Conclusions:

• The multicomponent device demonstrated efficacy and safety in managing LPRD.
• Early intervention in LPRD patients yielded superior therapeutic benefits.
• Findings support the use of non-acid-suppressive agents for LPRD, warranting further research.